X0609 4 2026-05-12 0001680367 Shattuck Labs, Inc. STTK 0001601942 Schreiber Taylor false C/O SHATTUCK LABS, INC. 500 W. 5TH STREET, SUITE 1200 AUSTIN TX 78701 true true false false Chief Executive Officer false Common Stock 2026-05-12 4 A false 25610 1.0846 A 122222 D Common Stock 2610750 I By Houghton Capital Holdings, LLC Warrants (Right to Buy) 1.0846 2026-05-12 4 M false 25610 D Common Stock 25610 0 D On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 25,610 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 25,610 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677. The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly. /s/ Andrew R. Neill, Attorney-in-Fact for Taylor Schreiber 2026-05-13